Published in Medical Letter on the CDC and FDA, December 28th, 2008
According to King Pharmaceuticals, Inc. (NYSE:KG), Pain Therapeutics' commercial partner for REMOXY, the FDA believes additional non-clinical data will be required to support the approval of REMOXY. The FDA has not requested or recommended additional clinical efficacy studies prior to approval. Pain...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.